Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Israel

Press release content from PR Newswire. The AP news staff was not involved in its creation.
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Israel
December 21, 2020 GMT
(PRNewsfoto/Seelos Therapeutics, Inc.)
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been issued Israeli patent number 241757 by the State of Israel Patent Office titled: “TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE”.
The issued patent covers a method of using trehalose (SLS-005) to treat several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, oculopharyngeal muscular dystrophy (OPMD), Huntington’s disease, spinocerebellar ataxia (SCA), spinal and bulbar muscular atrophy (SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick’s disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia, Parkinson’s disease, parkinsonism linked to chromosome 17 (FTDP-17), Alzheimer’s disease, and Friedreich ataxia (FA).

Related Keywords

New York , United States , Israel , Massachusetts , State Of Israel , Israeli , Seanm Healey , Anthony Marciano , Israel Patent Office , Prnewswire Seelos Therapeutics Inc , Seelos Therapeutics Inc , Head Of Corporate Communications , Nasdaq , Massachusetts General , Transcription Factor , Corporate Communications , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , இஸ்ரேல் , மாசசூசெட்ஸ் , நிலை ஆஃப் இஸ்ரேல் , இஸ்ரேலி , அந்தோணி மார்சியானோ , இஸ்ரேல் காப்புரிமை அலுவலகம் , சீலோஸ் சிகிச்சை இன்க் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் , நாஸ்டாக் , மாசசூசெட்ஸ் ஜநரல் , படியெடுத்தல் காரணி , பெருநிறுவன தகவல்தொடர்புகள் ,